Developing ecopipam, a dopamine D-1 antagonist, for the treatment of Tourette's syndrome, a neurological disorder manifested by motor and phonic tics.
- Year invested 2004
- Investment Stage Early
- Sectors
- Investment Status Current
- Website psyadonrx.com
- Company Status Private